Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
2015
Purpose
The combination of an mTOR inhibitor with 5-fluorouracil-based anticancer therapy is attractive because of preclinical evidence of synergy between these drugs. According to our phase I study, the combination of capecitabine and everolimus is safe and feasible, with potential activity in pancreatic cancer patients.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
38
References
42
Citations
NaN
KQI